Our Services
Medical Information
Helpful Resources
Published on: 7/21/2026
Wegovy (semaglutide) can trigger hypoglycemia symptoms like cold sweats, shaky hands, dizziness, and confusion by enhancing insulin release. Risk increases when Wegovy is combined with other diabetes medications (insulin or sulfonylureas), meals are skipped, alcohol is consumed on an empty stomach, or during intense exercise. Recognizing early warning signs and understanding personal risk factors is essential for safe use.
To treat suspected low blood sugar, follow the 15-15 rule: consume 15 grams of fast-acting carbohydrates (juice, glucose tablets, regular soda), wait 15 minutes, and recheck. Follow up with protein and complex carbs to stabilize levels. Consistent glucose monitoring, structured meal planning, and coordinating medications with your provider help prevent recurrence.
Because hypoglycemia symptoms can overlap with other conditions—and because Wegovy affects individuals differently—it's worth clarifying what your specific symptoms may indicate before your next dose or meal. A free, instant, online symptom check can help you identify likely causes, flag urgent warning signs, and guide your next steps, whether that means adjusting habits or contacting your doctor.
Reviewed for medical accuracy: 07/21/2026
Wegovy (semaglutide) is a prescription medication approved for weight management. While many people tolerate it well, some experience low blood sugar symptoms, including cold sweats and shaky hands. This guide will help you understand why this happens, how to recognize warning signs, and what steps to take if you suspect hypoglycemia.
Wegovy works by mimicking a natural hormone (GLP-1) that:
Because it affects insulin secretion, Wegovy can sometimes lower blood sugar more than expected, especially in certain situations.
Although it's uncommon in people not on other diabetes medications, these factors can raise your risk:
If you have type 2 diabetes and take both Wegovy and other glucose-lowering drugs, stay extra vigilant for hypoglycemia.
Early warning signs can be mild. Left untreated, symptoms may worsen. Watch for:
More severe signs include:
If you notice any of these, check your blood sugar immediately if you have a meter. A reading below 70 mg/dL (3.9 mmol/L) typically indicates hypoglycemia.
Prevention revolves around balance and planning:
While most hypoglycemic episodes can be managed at home, seek immediate medical care if you experience:
For milder or recurring low blood sugar symptoms, talk to your healthcare provider. They may:
If you're experiencing symptoms and want to better understand whether they may be related to Hypoglycemia, Ubie's free AI-powered symptom checker can help you assess your risk and determine appropriate next steps.
Wegovy can be a powerful tool for weight management, but it may affect blood sugar levels. Knowing the signs of low blood sugar—especially cold sweats and shaky hands—empowers you to act quickly. Use the "15-15 Rule," keep healthy snacks close by, and maintain regular monitoring.
Always remember: if anything feels life threatening or unusually severe, speak to a doctor right away. Early action can prevent complications and keep you safely on track with your treatment plan.
(References)
* Iacobellis G. Hypoglycemia with GLP-1 receptor agonists and SGLT2 inhibitors. J Clin Med. 2021 Jul 20;10(14):3194. doi: 10.3390/jcm10143194. PMID: 34300301.
* Storgaard H, Christiansen L, Astrup A, Lund A. Risk of Hypoglycemia with GLP-1 Receptor Agonists: A Systematic Review and Meta-Analysis. Diabetes Obes Metab. 2020 Jan;22(1):15-23. doi: 10.1111/dom.13840. Epub 2019 Sep 30. PMID: 31448558.
* Sun F, Wu S, Guo S, Wang C, Liu C, Zhou J, Li L, Leng J, Wang P, Zhang F, Li W, Li Q, Shi L, Yu X. Semaglutide and the Risk of Hypoglycemia in Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis. Diabetes Ther. 2019 Jun;10(3):1041-1051. doi: 10.1007/s13300-019-0628-9. Epub 2019 Apr 23. PMID: 31016597.
* Yabe D, Nomoto H, Utsunomiya K, Kaku K, Hanafusa T, Sasaki T, Sone H, Ito M, Haneda M; PIONEER 2 Japan investigators. Glucose-lowering efficacy and safety of once-weekly semaglutide in Japanese patients with type 2 diabetes receiving oral antidiabetic drugs: A 52-week, phase 3a, randomized, parallel-group, treat-to-target trial. Diabetes Obes Metab. 2018 Sep;20(9):2208-2216. doi: 10.1111/dom.13340. Epub 2018 Jun 21. PMID: 29882206.
* Buse JB, Nauck M, Forst T, Bergenstal RM, Blonde L, Guerci B, Han J, Kendall DM, Leiter LA, Meier M, Meneghini L, Russo V, Santos A, Schernthaner G, Schernthaner-Reiter MH. Safety and tolerability of GLP-1 receptor agonists. Cardiovasc Diabetol. 2017 Jul 25;16(1):14. doi: 10.1186/s12933-017-0534-0. PMID: 28743265.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.